Kevin O’Leary won’t touch cannabis as an investment but he loves the potential of psychedelic drugs. Why?
Kevin O’Leary won’t touch cannabis as an investment but he loves the potential of psychedelic drugs. Why?
Move over Big Pharma, Here Comes Silicon Valley Investment In Psychedelics Stocks Like Compass Pathways (CMPS)
After a quiet summer, trading volumes are soaring as investors pile back into psychedelic stocks.
IPO fever is sweeping through the psychedelics space.
MindMed stock has spiked higher by over 30%, on big volume. New investor focus on the deepest clinical research program in the industry.
Psychedelic stock warrants that are currently out of the money COULD produce big returns for investors.
The road to psychedelic drug success leads through functional mushrooms.
Canada stands out as the premier destination for psychedelic drug companies.
Compass has boosted its IPO financing by roughly 20% AND increased the unit price -- signalling strong interest in the psychedelic space.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now